What happened

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) director Laura Brege sold 14,167 shares after exercising options.

The filing says Brege still held 15,703 shares after the transactions, so the sale trimmed the position rather than closed it.

The shares were sold in two blocks at $94.05 and $94.74, far above the $16.71 exercise price, and the two blocks totaled about $1.33 million.

The derivative line ends at 0 after the exercise. The award was fully vested and carried a June 10, 2030 expiration, so it was ready to be turned into stock and sold.

Why it matters

Those sold shares were 47.4% of the holding before the Nov. 11 trade. That is a large reduction for one director, even if the filing stops short of a complete departure.

OptimistFi has argued that Mirum's equity depends on a commercial franchise that keeps growing, retains payer access and supports a premium multiple.

This filing leaves that operating story unchanged, but it does show an insider reducing direct equity exposure after the award had already vested. It also shows the cash value of the sale without saying anything about the business itself.

The shares were sold in two transactions on the same day as the option exercise, and the filing shows the award's vesting date and expiration date. That makes the transaction look like executed compensation monetization rather than a new bet against the company.

The record covers one director and one day's transactions, so it establishes the size of the move but not a broader pattern. It also shows that the option exercise, not a new award, supplied the shares that were later sold.

What's next

Mirum's next quarterly report will be the next check on whether the commercial franchise is still converting revenue growth into operating cash and nearing operating profitability. A stronger report would support OptimistFi's view, while a weaker one would put the insider sale in a colder light.

Sources checked automatically Nov 14, 2026 · Human review: none
Thesis impactMIRM: no published thesis yet.